The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations
Tóm tắt
There are now five targeted agents, i.e. sorafenib, sunitinib, temsirolimus, bevacizumab (in combination with interferon) and everolimus, that have been shown to improve the outcome in patients with metastatic clear cell renal cell carcinoma (mRCC), in randomized controlled trials (RCTs). Compared with the period when cytokines were the only systemic intervention known to have any activity, decisions on medical management are now complex. Clinicians must seek to adjust therapy to the circumstances of the individual patient, and consider the sequencing of agents. In this context, several expert groups have sought to provide treatment guidelines. As in other diseases, guidelines for mRCC seek to establish evidence‐based recommendations for best clinical practice and to encourage their widespread use. Data from phase III trials (level 1 evidence) are an essential element in this process, and guidelines need continual updating in the light of new findings. However, there are inevitably questions that large RCTs have not directly addressed. This is the case for major subgroups of the mRCC population, e.g. the elderly and those with comorbidities. In these circumstances, less well‐controlled sources of data, and clinical experience, have a role to play. Certain guidelines (although not all) acknowledge the contribution that such sources of evidence can make.
Từ khóa
Tài liệu tham khảo
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Available at:http://www.nccn.org. Accessed August 2008
Bukowski R, 2007, Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis, J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5023
Figlin RA, 2008, Overall survival with sunitinib versus interferon (IFN) ‐alfa as first‐line treatment of metastatic renal cell carcinoma (mRCC), J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.5024
RiniBI HalabiS RosenbergJEet al.CALGB 90206. A Phase III trial of bevacizumab plus interferon‐alpha versus interferon‐alpha monotherapy in metastatic renal cell carcinoma.ASCO Genitourinary Cancers Symposium2008; Abstract 5033
De ReijkeTM BellmuntJ Van PoppelH MarreaudS AaproM.EORTC‐GU group expert opinion on metastatic renal cell cancer.Eur J Cancer2008(in press)
Canadian Kidney Cancer Forum., 2008, Management of kidney cancer. Canadian Kidney Cancer Forum Consensus Statement, Can Urol Assoc J, 2, 175
Norwegian Directorate of Health.Nasjonalt handlingsprogram med retningslinjer for diagnostikk behandling og oppfølging av pasienter med nyrecellekreft. Available at:http://www.shdir.no. Accessed August 2008
Dham A, 2007, Sequential therapy with sorafenib and sunitinib in renal cell carcinoma, J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5106
Sablin MP, 2007, Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients, J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5038
EscudierB RavaudA BracardaSet al.Efficacy and safety of first‐line bevacizumab (BEV) plus interferon‐a2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC).ASCO Genitourinary Cancers Symposium2008; Abstract 358
Dutcher JP, 2007, Correlation of survival with tumor histology, age and prognostic risk group for previously treated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon‐alpha (IFN), J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.5033
Bukowski RM, 2008, Safety and efficacy of sorafenib in elderly patients (pts) >65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America, J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.5045
EisenT OudardS SzczylikCet al.Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: subgroup analysis of The Approaches in Renal Cancer Global Evaluation Trial (TARGETs).22nd Annual EAU Congress2008 abstract 964
RiniBI.Renal Cell Carcinoma: What Really Matters?Presented at the American Society of Clinical Oncology Annual Meeting 2008. Available at:http://www.asco.org. Accessed August 2008